In news that is hardly surprising, Pfizer CEO Albert Bourla said on December 8th that people may need a fourth schedule of the COVID jab needed sooner than anticipated in light of the Omicron variant of COVID flying around.
This is, of course, in relation to the same variant that we at Red Voice Media have previously reported on that has thus far been mild in symptoms with respect to confirmed cases.
Pfizer CEO Bourla said that the company’s early analysis in expediting jab number four was based on a synthetic, lab-created clone of the variation and that further evidence from testing against the genuine virus is required. According to Bourla, the real-world findings will be more accurate and will be available in the following two weeks.
“When we see real-world data, [it] will determine if the omicron is well covered by the third dose and for how long. And the second point, I think we will need a fourth dose.”
In previous statements pertaining to the new COVID variant, Bourla had stated that gearing up for jab number four should be roughly 12 months after shot recipients snatched the third dose. But now, Bourla is saying that people need to start getting ready sooner than anticipated for the fourth jab.
“With omicron, we need to wait and see because we have very little information. We may need it faster.”
While folks await the arrival of the data regarding the Omicron variant, Bourla says that the best thing to do is start rolling out jab session number three right now before it’s too late.
“A third dose will give very good protection I believe.”
Outside of incessantly pushing extra jabs for everyone in the family, Pfizer has recently submitted their application to the FDA for an emergency authorization for their oral antiviral pill, Paxlovid, which was developed to help prevent severe COVID cases.
Pfizer will reportedly have the full data pertaining to clinical trials of Paxlovid in the coming days, which the pill thus far has demonstrated an 89% reduction in hospitalization and death in interim data from November.
As for a jab solely dedicated to combatting the Omicron variant, Pfizer and BioNTech could ostensibly have one crafted by March of 2022 if one is genuinely needed.
This piece was written by Gregory Hoyt on December 8, 2021. It originally appeared in RedVoiceMedia.com and is used by permission.
The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of LifeZette.